Skip to main navigation ABOUT US TECHNOLOGY PIPELINE INVESTORS CAREERS PRESS RELEASES Year 2021 MORPHIC ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES November 16, 2021 WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation in the upcoming investor conferences: Dr. Bruce N. Read More MORPHIC PRESENTS PRECLINICAL DATA FROM ΑVΒ8 INTEGRIN PROGRAM AT THE SITC ANNUAL MEETING November 15, 2021 αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination immunotherapy to drive anti-tumor response via TGFβ pathway WALTHAM, Mass., Nov. Read More MORPHIC ANNOUNCES CORPORATE HIGHLIGHTS AND THIRD QUARTER 2021 FINANCIAL RESULTS November 4, 2021 MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D., to Morphic Board of Directors WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic Read More MORPHIC TO PARTICIPATE IN JEFFERIES IBD THERAPEUTICS SUMMIT October 12, 2021 WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part Read More MORPHIC THERAPEUTIC ANNOUNCES PARTICIPATION IN SEPTEMBER INVESTOR CONFERENCES September 1, 2021 WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: Dr. Read More MORPHIC THERAPEUTIC ANNOUNCES APPOINTMENT OF NISHA NANDA, PH.D., TO BOARD OF DIRECTORS August 23, 2021 WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Read More MORPHIC ANNOUNCES CORPORATE HIGHLIGHTS AND SECOND QUARTER 2021 FINANCIAL RESULTS August 4, 2021 MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from αvβ8 program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models Announced Read More MORPHIC REPORTS NEW DATA FROM POSITIVE PHASE 1 STUDY OF MORF-057, ORAL INTEGRIN INHIBITOR CANDIDATE FOR IBD July 9, 2021 MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET Read More MORPHIC THERAPEUTIC TO HOST ANALYST AND INVESTOR CALL ON JULY 9, 2021 July 2, 2021 Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of Read More MORPHIC THERAPEUTIC TO PRESENT POSITIVE PHASE 1 DATA FOR MORF-057 AT ECCO’21 VIRTUAL CONGRESS May 28, 2021 Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results Read More PAGINATION Current page 1 Page 2 Page 3 Next page next › Last page last » 35 Gatehouse Drive, A2 Waltham, MA 02451 (781) 996-0955 info@morphictx.com © 2021 Morphic Therapeutic Privacy Statement | Terms of Service